AIM ImmunoTech Inc (AIM)
0.4042
+0.01
(+3.64%)
USD |
NYAM |
May 02, 16:00
0.4034
0.00 (0.00%)
Pre-Market: 20:00
AIM ImmunoTech Enterprise Value: 7.789M for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 7.789M |
| May 01, 2024 | 7.080M |
| April 30, 2024 | 8.004M |
| April 29, 2024 | 8.173M |
| April 26, 2024 | 8.987M |
| April 25, 2024 | 7.904M |
| April 24, 2024 | 9.076M |
| April 23, 2024 | 8.852M |
| April 22, 2024 | 8.578M |
| April 19, 2024 | 10.82M |
| April 18, 2024 | 11.42M |
| April 17, 2024 | 11.36M |
| April 16, 2024 | 12.33M |
| April 15, 2024 | 11.81M |
| April 12, 2024 | 15.66M |
| April 11, 2024 | 18.26M |
| April 10, 2024 | 15.46M |
| April 09, 2024 | 12.27M |
| April 08, 2024 | 12.01M |
| April 05, 2024 | 12.18M |
| April 04, 2024 | 14.06M |
| April 03, 2024 | 11.38M |
| April 02, 2024 | 10.07M |
| April 01, 2024 | 12.08M |
| March 28, 2024 | 11.12M |
| Date | Value |
|---|---|
| March 27, 2024 | 9.725M |
| March 26, 2024 | 9.175M |
| March 25, 2024 | 9.224M |
| March 22, 2024 | 9.406M |
| March 21, 2024 | 6.327M |
| March 20, 2024 | 7.265M |
| March 19, 2024 | 7.506M |
| March 18, 2024 | 6.032M |
| March 15, 2024 | 3.823M |
| March 14, 2024 | 3.995M |
| March 13, 2024 | 5.296M |
| March 12, 2024 | 5.050M |
| March 11, 2024 | 5.296M |
| March 08, 2024 | 6.180M |
| March 07, 2024 | 6.474M |
| March 06, 2024 | 6.744M |
| March 05, 2024 | 7.014M |
| March 04, 2024 | 7.014M |
| March 01, 2024 | 7.290M |
| February 29, 2024 | 7.309M |
| February 28, 2024 | 7.309M |
| February 27, 2024 | 7.756M |
| February 26, 2024 | 7.751M |
| February 23, 2024 | 8.124M |
| February 22, 2024 | 7.506M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-21.35M
Minimum
Dec 29 2022
152.07M
Maximum
Mar 09 2020
18.33M
Average
6.744M
Median
Mar 06 2024
Enterprise Value Benchmarks
| Perspective Therapeutics Inc | 1.008B |
| Protalix BioTherapeutics Inc | 60.43M |
| Electromed Inc | 142.82M |
| Xtant Medical Holdings Inc | 128.57M |
| Armata Pharmaceuticals Inc | 158.79M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.58M |
| Revenue (Quarterly) | 0.065M |
| Total Expenses (Quarterly) | 14.07M |
| EPS Diluted (Quarterly) | -0.26 |
| Gross Profit Margin (Quarterly) | 81.54% |
| Profit Margin (Quarterly) | -19.35K% |
| Earnings Yield | -148.4% |
| Normalized Earnings Yield | -149.54 |